Abstract: A susceptor for a CVD-reactor includes insertion openings arranged in a bearing surface of the susceptor. An insertion section of a positioning element is inserted into one of the insertion openings. The insertion section forms positioning flanks with a section projecting from the insertion opening for fixing the position of a substrate. The insertion openings each have side walls and a base. The insertion section comprises bearing areas adjacent to the side walls of the insertion openings and a lower side of the positioning element facing the base of the insertion opening. The base of the insertion opening is separated from the lower side of the positioning element by a first distance. An edge protruding section of the positioning element is separated from a section of the bearing surface of the susceptor by a second distance.

Abstract: A susceptor for a CVD-reactor includes insertion openings arranged in a bearing surface of the susceptor. An insertion section of a positioning element is inserted into one of the insertion openings. The insertion section forms positioning flanks with a section projecting from the insertion opening for fixing the position of a substrate. The insertion openings each have side walls and a base. The insertion section comprises bearing areas adjacent to the side walls of the insertion openings and a lower side of the positioning element facing the base of the insertion opening. The base of the insertion opening is separated from the lower side of the positioning element by a first distance. An edge protruding section of the positioning element is separated from a section of the bearing surface of the susceptor by a second distance.

Abstract: A new family of analogues of NADP+ or NADPH, their preparation and their application in therapeutics.

Abstract: The present invention relates to a signature comprising at least 2 cycling hypoxia markers. The present invention also relates to a non-invasive method for the prognosis of cancer in a subject, wherein said method comprises assessing the expression of markers of a signature of the invention in a sample from said subject; and to a kit for implementing this non-invasive method.

Abstract: The present invention relates to novel compounds. The present invention also relates to the compounds for use as a medicine, more in particular for the prevention or treatment of cancer, more in particular cancers expressing MCT1 and/or MCT4. The present invention also relates to a method for the prevention or treatment of cancer in animals or humans by using the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds and to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of cancer. The present invention also relates to processes for the preparation of the compounds.

Abstract: Novel phenazine derivatives of formula (I) are disclosed. In particular, substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines are disclosed. The compounds can be used as anti-angiogenic and/or anti-tumor agents.

Abstract: The invention relates to a device for coating substrates having a process chamber (1) disposed in a reactor housing and a two-part, substantially cup-shaped susceptor (2, 3) disposed therein, forming an upper susceptor part (2) with the cup floor thereof having a flat plate (2?) and a lower susceptor part (3) with the cup side walls thereof, the outer side (4) of the plate (2?) of the upper susceptor part (2) facing upwards toward the process chamber (1) and forming a contact surface for at least one substrate, the upper susceptor part (2) contacting a front edge (3?) of the lower susceptor part (3) at the edge of said upper susceptor part (2), the lower susceptor part (3) being supported by a susceptor carrier (6), and heating zones (A, B, C) for heating the upper susceptor part (2) being disposed below the plate (2?).

Abstract: A new family of analogues of NADP+ or NADPH, their preparation and their application in therapeutics.

Abstract: The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.

Abstract: The invention relates to a device for coating substrates having a process chamber (1) disposed in a reactor housing and a two-part, substantially cup-shaped susceptor (2, 3) disposed therein, forming an upper susceptor part (3) with the cup floor thereof having a flat plate (2) and a lower susceptor part (3) with the cup side walls thereof, the outer side (4) of the plate (2) of the upper susceptor part (2) facing upwards toward the process chamber (1) and forming a contact surface for at least one substrate, the upper susceptor part (2) contacting a front edge (3?) of the lower susceptor part (3) at the edge of said upper susceptor part (2), the lower susceptor part (3) being supported by a susceptor carrier (6), and heating zones (A, B, C) for heating the upper susceptor part (2) being disposed below the plate (2?).

Abstract: The invention relates to a device for coating a plurality of substrates (3) which are regularly arranged on a bearing surface (2) of a susceptor (1) associated to a process chamber (14), wherein the bearing surface (2) forms abutment flanks (5) for the edge mounting of each substrate (3). In order to reduce the free susceptor surface to a minimum, it is proposed that the abutment flanks of the lateral walls (5) are formed by bases (4) which project from the bearing surface (2) and are separated at a distance from one another. Said bases are arranged on the corner points (10) of a honeycomb structure and have an outline essentially corresponding to an equilateral triangle with inwardly curved sides (5).

Abstract: The present invention is related to a pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a

Abstract: The present invention is related to a pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a

Abstract: A compound for use as a medicament for the modulation of angiogenesis through the tackling of the intracellular free cholesterol-caveolin1-eNOS-NO pathway.